NCT04672824View on ClinicalTrials.gov

A Study to Assess the New Candidate Rift Valley Fever Virus Vaccine in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2022

Primary Completion Date

December 15, 2022

Study Completion Date

December 15, 2022

Conditions
RVFRift Valley Fever
Interventions
BIOLOGICAL

ChAdOx1 RVF

Single dose ChAdOx1 vectored vaccine

OTHER

Saline

0.5ml saline placebo

Trial Locations (1)

Unknown

MRC/UVRI and LSHTM Uganda Research Unit, Entebbe

All Listed Sponsors
collaborator

MRC/UVRI and LSHTM Uganda Research Unit

OTHER

lead

University of Oxford

OTHER